Literature for tipranavir (A02.001 inhibitor)

(Topics flags: S Structure, I Inhibitor, E Expression, V Review. To select only the references relevant to a single topic, click the link above. See explanation.)

2017
1. Clark,K.M., Jenkins,J.L., Fedoriw,N. and Dumont,M.E.
   Human CaaX protease ZMPSTE24 expressed in yeast: structure and inhibition by HIV protease inhibitors
   Protein Sci26, 242-257. PubMed  Europe PubMed DOI  E  S  I
2012
2. Aoki,M., Danish,M.L., Aoki-Ogata,H., Amano,M., Ide,K., Das,D., Koh,Y. and Mitsuya,H.
   Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1
   J Virol86, 13384-13396. PubMed  Europe PubMed DOI  I
2011
3. Elgadi,M.M. and Piliero,P.J.
   Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial
   Drugs R D11, 295-302. PubMed  Europe PubMed DOI  I
4. Wang,Y., Liu,Z., Brunzelle,J.S., Kovari,I.A., Dewdney,T.G., Reiter,S.J. and Kovari,L.C.
   The higher barrier of darunavir and tipranavir resistance for HIV-1 protease
   Biochem Biophys Res Commun412, 737-742. PubMed  Europe PubMed DOI  I
2010
5. Reddy,A.S., Kumar,S. and Garg,R.
   Hybrid-genetic algorithm based descriptor optimization and QSAR models for predicting the biological activity of Tipranavir analogs for HIV protease inhibition
   J Mol Graph Model28, 852-862. PubMed  Europe PubMed DOI  I
2008
6. Norelli,S., El Daker,S., D'Ostilio,D., Mele,F., Mancini,F., Taglia,F., Ruggieri,A., Ciccozzi,M., Cauda,R., Ciervo,A., Barreca,M.L., Pistello,M., Bendinelli,M. and Savarino,A.
   Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1
   Curr HIV Res6, 306-317. PubMed  Europe PubMed DOI  I
2007
7. Muzammil,S., Armstrong,A.A., Kang,L.W., Jakalian,A., Bonneau,P.R., Schmelmer,V., Amzel,L.M. and Freire,E.
   Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations
   J Virol81, 5144-5154. PubMed  Europe PubMed DOI  I
2006
8. [YEAR:23-8-2006]Baxter,J.D., Schapiro,J.M., Boucher,C.A., Kohlbrenner,V.M., Hall,D.B., Scherer,J.R. and Mayers,D.L.
   Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir
   J Virol80, 10794-10801. PubMed  Europe PubMed DOI  I
9. Mastrolorenzo,A., Rusconi,S., Scozzafava,A. and Supuran,C.T.
   Inhibitors of HIV-1 protease: 10 years after
   Expert Opin Ther Pat16, 1067-1091. DOI  V  I
2005
10. Ellis,J.M. and Ross,J.
    A novel nonpeptidic protease inhibitor
    Formulary40,  I
11. Kandula,V.R., Khanlou,H. and Farthing,C.
    Tipranavir: a novel second-generation nonpeptidic protease inhibitor
    Expert Rev Anti Infect Ther3, 9-21. PubMed  Europe PubMed DOI  I
2004
12. de Mendoza,C. and Soriano,V.
    Resistance to HIV protease inhibitors: mechanisms and clinical consequences
    Curr Drug Metab5, 321-328. PubMed  Europe PubMed DOI  I
2003
13. Mehandru,S. and Markowitz,M.
    Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection
    Expert Opin Investig Drugs12, 1821-1828. PubMed  Europe PubMed DOI  I
14. Yeni,P.
    Tipranavir: a protease inhibitor from a new class with distinct antiviral activity
    J Acquir Immune Defic Syndr34 Suppl 1, S91-S94. PubMed  Europe PubMed DOI  I
1999
15. Thaisrivongs,S. and Strohbach,J.W.
    Structure-based discovery of Tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor
    Biopolymers51, 51-58. PubMed  Europe PubMed DOI  I